Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Eszopiclone (Lunesta) In San Francisco,.cde2"

Looking for quality documents?
corporate icon
Perfusion Cell Culture
Perfusion, a cornerstone of upstream continuous bioprocessing, has been practiced since the 1980s to maximize facility utilization, expand process flexibility and minimize costs. Today, novel cell retention devices and single-use technologies, with sophisticated control logic, simplify implementation.
video icon
OPUS Europe packing
corporate icon
Peptide Mapping
Challenge: Sequence verification via traditional LC-MS peptide mapping is resource-intensive and slow. Our Solution: ZipChip enables rapid, high-resolution peptide mapping at-line to confirm sequence integrity and detect PTMs.
news icon
OPUS® Columns win Design Excellence Awards: Winner - GOOD DESIGN 2015 Award for Design Excellence - Industry
external link icon
Repligen Launches AAV Affinity Resins for Gene Therapy Purification
AVIPure® affinity resins address the market need for high performance and caustic stability WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of three advanced affinity chromatography resins for use in gene therapy manufacturing workflows. The resins – AVIPure ® - AAV9, AVIPure ® - AAV8, and AVIPure ® - AAV2 – were developed by Avitide LLC, a Repligen company, and are specific to the major adeno-associated virus (AAV) gene therapy vectors used today. AAV vectors are the leading platform for gene delivery for the treatment of a variety of human diseases 1 . Vikas Gupta, Vice President and General Manager, Downstream Bioprocessing and Gene Therapy at Repligen said, “These AVIPure resins are powerful tools in our growing arsenal of unique and differentiated solutions for gene therapy manufacturing. The outstanding performance of these resins,
external link icon
Repligen Reports Second Quarter 2018 Financial Results
Record quarterly revenue of $47.7 million represents 47% year-over-year growth Revenue guidance raised to $185-$190 million for full year 2018 WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter and first half of 2018. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2018, updates to our 2018 financial guidance and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “Our second quarter financial performance was led by record direct sales of our filtration and chromatography products, which nearly doubled year-over-year and delivered greater than 25% organic growth. Our Spectrum products continue to perform well, with 29% pro forma growth over the second quarter of 2017. In our Proteins franchise, we
external link icon
Repligen Reports Second Quarter 2017 Financial Results
Record quarterly revenue of $32.5 million First half 2017 revenue growth of 16% or 18% at constant currency Enters agreement to acquire Spectrum, Inc., which closed August 1 Prices follow-on offering which netted proceeds of $129 million Raises EPS guidance for 2017 WALTHAM, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter ended June 30, 2017. Detailed in this press release are the Company's performance highlights for the quarter, followed by updated financial guidance for the year 2017 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said “I’m extremely pleased with our accomplishments and performance during the second quarter.  We executed on our financial and strategic goals, reporting record quarterly revenue and year-to-date revenue growth of 18%. We signed
external link icon
Repligen Reports Second Quarter 2016 Financial Results
WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the second quarter ended June 30, 2016. Detailed in this press release are the Company's performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We continue to be encouraged by the strength in demand for our bioprocessing products and the positive trends in our industry. We achieved record revenue of $29.2 million in the second quarter of 2016, an increase of 36% from the same period in 2015, driven by strong demand for OPUS® purification columns, XCell™ ATF systems and growth factors. It was also an important quarter in terms of executing on our long-term growth strategy. In April, we acquired Atoll GmBH (“Atoll”), and in May we
external link icon
Repligen Reports Second Quarter 2015 Financial Results
Product Sales Increase 38% to a Record $21.5 Million 
 
Conference Call and Webcast Today at 8:30 a.m. ET  WALTHAM, Mass., Aug. 06, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the second quarter and six-month (year-to-date) periods ended June 30, 2015. Below are the Company’s performance highlights, followed by updated financial guidance for the year 2015 and access information for today’s webcast and conference call. Second Quarter and Year-to-Date Financial Highlights   Product revenue for the second quarter of 2015 was $21.5 million compared to $15.6 million for the second quarter of 2014, an increase of 38% which includes a negative impact of 11% from foreign currency translation. For the six-month period, product revenue was $42.3 million compared to $29.9 million for the same period in 2014, an increase of 41%. Total revenue
external link icon
Repligen Reports Second Quarter 2014 Financial Results
Product Revenue Increases 19.5% to a Record $15.6 Million Product Gross Profit Increases 15.1% to a Record $8.9 Million Conference Call and Webcast Today at 8:30 a.m. EDT WALTHAM, Mass., Aug. 11, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for its second quarter ended June 30, 2014. The Company's financial and business highlights for the second quarter and year-to-date follow, as well as updated financial guidance for the year 2014. Second Quarter Financial Highlights: Product revenue for the second quarter of 2014 was $15.6 million, an increase of 19.5% over the second quarter of 2013. Product revenue for the 2014 period includes approximately $500,000 from ATF System sales as a result of the Company's acquisition of the business of Refine Technology on June 2, 2014.
  Product gross profit increased 15.1% to $8.9 million or 57.1% of product revenue for the second quarter of 2014 compared to $7.7 million or 59.3% of product